Dr. Clark is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
# Hematolo
Boston, MA 02114Phone+1 617-724-4000Fax+1 617-726-0452
Summary
- Dr. Jeffrey Clark is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital, Dana-Farber Cancer Institute, and Newton-Wellesley Hospital. He received his medical degree from Tufts University School of Medicine and has been in practice 39 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in esophageal cancer, squamous cell carcinoma of the esophagus, cholangiocarcinoma, adenocarcinoma of the lung, and immunotherapy. He has more than 100 publications and over 500 citings.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1981 - 1985
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1978 - 1981
Tufts University School of MedicineClass of 1978
Certifications & Licensure
MA State Medical License 1994 - 2025
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
RI State Medical License 1988 - 1996
MD State Medical License 1984 - 1988- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer Start of enrollment: 2000 May 01
- Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer Start of enrollment: 2002 Aug 01
- A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer Start of enrollment: 2006 Apr 19
Publications & Presentations
PubMed
- 252 citationsAntitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Jeffrey W. Clark, Jared Weiss, Sai-Hong Ignatius Ou, D. Ross Camidge
Nature Medicine. 2020-01-13 - 956 citationsActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.D. Ross Camidge, Yung-Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella-Garcia
The Lancet. Oncology. 2012-10-01 - 3454 citationsAnaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerEunice L. Kwak, Yung-Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon
The New England Journal of Medicine. 2010-10-28
Other
- Adjuvant therapy for resected stage III (node-positive) colon cancerClark JW, Sanoff HK
http://www.uptodate.com/contents/adjuvant-therapy-for-resected-stage-iii-node-positive-colon-cancer
UpToDate, Wolters Kluwer Health - 2013-04-09 - Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trialsClark JW, Grothey A
http://www.uptodate.com/contents/systemic-chemotherapy-for-metastatic-colorectal-cancer-completed-cl
UpToDate, Wolters Kluwer Health - 2013-02-25 - Systemic chemotherapy for metastatic colorectal cancer: General principlesClark JW, Grothey A
http://www.uptodate.com/contents/systemic-chemotherapy-for-metastatic-colorectal-cancer-general-prin
UpToDate, Wolters Kluwer Health - 2013-03-18 - Join now to see all
Press Mentions
5 Colon Cancer Symptoms You Should Know—Even if You’re YoungApril 20th, 2018
Colon Cancer Patient Story: Rick & Sally MastalerzJune 29th, 2023
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
